My Portfolio
+
LINK YOUR PORTFOLIO

Lantheus Holdings Inc LNTH:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 06/03/26 EDT
100.25UNCH (UNCH)
Volume
34,270
Close
100.25quote price arrow up+3.95 (+4.10%)
Volume
1,046,403
52 week range
47.25 - 103.89
Loading...
  • Open96.46
  • Day High101.66
  • Day Low95.00
  • Prev Close96.30
  • 52 Week High103.89
  • 52 Week High Date05/22/26
  • 52 Week Low47.25
  • 52 Week Low Date08/06/25

Key Stats

  • Market Cap6.527B
  • Shares Out65.11M
  • 10 Day Average Volume1.20M
  • Dividend-
  • Dividend Yield-
  • Beta-0.04

KEY STATS

  • Open96.46
  • Day High101.66
  • Day Low95.00
  • Prev Close96.30
  • 52 Week High103.89
  • 52 Week High Date05/22/26
  • 52 Week Low47.25
  • 52 Week Low Date08/06/25
  • Market Cap6.527B
  • Shares Out65.11M
  • 10 Day Average Volume1.20M
  • Dividend-
  • Dividend Yield-
  • Beta-0.04

RATIOS/PROFITABILITY

  • EPS (TTM)4.14
  • P/E (TTM)24.20
  • Fwd P/E (NTM)18.67
  • EBITDA (TTM)369.263M
  • ROE (TTM)23.48%
  • Revenue (TTM)1.546B
  • Gross Margin (TTM)60.48%
  • Net Margin (TTM)18.05%
  • Debt To Equity (MRQ)47.05%

EVENTS

  • Earnings Date08/04/2026(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. Its product categories include oncology, neurology, cardiology, and strategic partnerships and others. Its products include PYLARIFY, Neuraceq, and DEFINITY. PYLARIFY TruVu is indicated for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial...
Mary Heino
Executive Chairman of the Board, Interim Executive Officer
Robert Marshall Jr.
Chief Financial Officer, Treasurer
Address
331 Treble Cove Road
North Billerica, MA
01862
United States